NEW YORK, August 15, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Novartis AG (NYSE: NVS), Chicago Bridge & Iron Company N.V. (NYSE: CBI), L-3 Communications Holdings Inc. (NYSE: LLL) and Emerson Electric Co. (NYSE: EMR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5765-100free.
Alexion Pharmaceuticals, Inc. Research Reports
On August 12, 2014, the stock Alexion Pharmaceuticals, Inc. (Alexion) declined 0.72% to end the session at $160.62. During the session, the stock opened at $160.99, and fluctuated in the range of $159.23 - $161.39, with a total of 0.86 million shares changing hands. Over the last one month, the Company's stock has declined by 1.59%, compared to the NASDAQ 100 index which rose 0.02% during the same period. The full research reports on Alexion are available to download free of charge at:
Novartis AG Research Reports
On August 11, 2014, Novartis AG (Novartis) announced that it will present a new data revealing the reduction in cardiovascular (CV) deaths with the Company's LCZ696, in patients with heart failure with reduced ejection fraction (HF-REF) at the European Society of Cardiology (ESC) Congress 2014, on August 31, 2014 at 8.30 a.m. CET. Novartis said that the study PARADIGM-HF, which covered 8,442 patients, met the primary endpoint showing that LCZ696 reduced heart failure hospitalizations along with CV deaths. The Company informed that as millions of people across the world live with high risk of death due to heart failure, hence the FDA has granted LCZ696 Fast Track designation. Novartis stated that the Fast Track designation can accelerate the review of new medicines intended to treat life-threatening conditions and also allows for rolling submission in the US which it expects to complete by the end of 2014. The full research reports on Novartis are available to download free of charge at:
Chicago Bridge & Iron Company N.V. Research Reports
On August 7, 2014, Chicago Bridge & Iron Company N.V. (CB&I) issued a press release to congratulate the Cameron liquefaction project sponsors for approving a final investment decision for the planned development of the natural gas liquefaction and export project planned at the site of Sempra Energy's Cameron LNG receipt terminal in Hackberry, Louisiana. CB&I informed that the sponsors of the project are Sempra LNG, GDF SUEZ S.A., Mitsui & Co., Ltd. and Mitsubishi Corporation through a related Company jointly established with Nippon Yusen Kabushiki Kaisha. According to the Company, the three-train natural gas liquefaction facilities will have an export capability of 12 million tonnes per annum of liquefied natural gas (LNG), or approximately 1.7 billion cubic feet per day. CB&I expects to commence construction on the project later this year subject to final regulatory approvals and satisfaction of certain other conditions. The Company expects all three trains to commence operations during 2018. "CCJV, a joint venture contractor of CB&I and Chiyoda International Corporation for the project, congratulates Sempra and the Cameron liquefaction project sponsors on the approval of the final investment decision," said Patrick K. Mullen, President of CB&I's Engineering, Construction and Maintenance operating group. The full research reports on CB&I are available to download free of charge at:
L-3 Communications Holdings Inc. Research Reports
On July 31, 2014, L-3 Communications Holdings Inc. (L-3) reported its preliminary financial results for Q2 FY 2014 (period ended June 27, 2014) due to an ongoing review related to the accounting matters at its Aerospace Systems segment. The Company's consolidated net sales during the quarter rose 5.7% YoY to $3.0 billion. Operating margin stood at 8.9% versus 9.4% in Q2 FY 2013. Net income attributable to L-3 stood at $156 million, or $1.75 per diluted share, versus $181 million or $1.99 per diluted share in Q2 2013. Based on review, the Company on a preliminary basis updated its guidance and expects full-year FY 2014 net sales to be between $12.0 billion to $12.2 billion and operating margin to be 9.9%. The full research reports on L-3 are available to download free of charge at:
Emerson Electric Co. Research Reports
On August 5, 2014, Emerson Electric Co. (Emerson) announced its Q3 FY 2014 financial results (period ended June 30, 2014). The Company reported net income attributable to stockholders of $728.0 million or $1.03 per diluted share in Q3 FY 2014, compared to $194.0 million or $0.27 per diluted share in Q3 FY 2013. Excluding prior year one-time charges, the Company's net income per share of $1.03 grew 6.2% YoY. Emerson's bottom line missed the average expectations of $1.06 per share in a Reuters' poll of analysts. The Company said that headwind from difficult tax rate comparisons reduced its earnings by $0.03 per share in the quarter. Net sales of the Company were down 0.5% YoY at $6.3 billion. Citing the uncertainty around economic development across the world, Emerson now expects full-year FY 2014 underlying sales growth to remain at lower end of previously communicated range of 3%-5%. The full research reports on Emerson are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review